Emicizumab granted priority review for hemophilia A without inhibitors

Print Friendly, PDF & Email


Bleeding human finger
By Crystal (Crystl) from Bloomington, USA - Flickr
The US Food and Drug Administration (FDA) has granted priority review for emicizumab (Hemlibra®) for adults and children with hemophilia A without factor VIII inhibitors. Earlier this year, the agency awarded emicizumab breakthrough therapy designation for the same population. Emicizumab is a bispecific factor... [Read Article]
Print Friendly, PDF & Email

Injectable hydrogel bandages reduce internal bleeding

Print Friendly, PDF & Email


Hydrogels
Photo by Kathy Atkinson,
University of Delaware
Researchers are developing an injectable hydrogel bandage that they say can rapidly stop internal bleeding, potentially saving lives in emergency situations. They report the hydrogel bandage can accelerate clotting time two-fold. Additionally, when the team attached vascular endothelial growth factor (VEGF) to the nanoparticle component of... [Read Article]
Print Friendly, PDF & Email

FDA clears device for treatment of PE

Print Friendly, PDF & Email


CT scan showing a PE
Image from Medical
College of Georgia
The US Food and Drug Administration (FDA) has granted 510(k) clearance to the FlowTriever System for the treatment of pulmonary embolism (PE). This makes the FlowTriever System the first and only thrombectomy device cleared by the FDA for the treatment of PE. The... [Read Article]
Print Friendly, PDF & Email

Therapy can extend half-life of FVIII

Print Friendly, PDF & Email


Antihemophilic factor
Preliminary data suggest an investigational therapy can extend the half-life of factor VIII (FVIII) in patients with severe hemophilia A. Researchers are testing the therapy, BIVV001, in a phase 1/2a trial and have reported results in 4 patients. BIVV001 extended the half-life of FVIII to 37 hours, with an average FVIII activity... [Read Article]
Print Friendly, PDF & Email

Emicizumab reduces bleeding in hemophilia A

Print Friendly, PDF & Email


Emicizumab (Hemlibra)
Photo from Business Wire
Final results from the HAVEN 3 study suggest emicizumab prophylaxis can reduce bleeding in hemophilia A patients without factor VIII inhibitors. Compared to patients who did not receive prophylaxis, those who received emicizumab prophylaxis had a 96% to 97% reduction in treated bleeds and a 94% to 95%... [Read Article]
Print Friendly, PDF & Email

FDA approves drug for thrombocytopenia in CLD

Print Friendly, PDF & Email


Thrombocytopenia
Image from Erhabor Osaro
The US Food and Drug Administration (FDA) has approved avatrombopag (DOPTELET®), a second-generation thrombopoietin receptor agonist. Avatrombopag is now approved to treat thrombocytopenia in adults with chronic liver disease (CLD) who are scheduled to undergo a procedure. Dova Pharmaceuticals, Inc., plans to launch the drug in June. ... [Read Article]
Print Friendly, PDF & Email